The importance of collagen quality in heart performance and the impact of LOX/LOXLs on cardiac fibroblast function highlight the interest of LOX/LOXLs-inhibitory therapies to slow HF progression and limit the detrimental impact of cardiac remodeling in response to myocardial infarction [98,101,102,103]. This evidence concerns the gene LOX and myocardial infarction.